Preventing Cognitive Decline With Metformin

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomised control study of metformin in people with mild cognitive impairment and without diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Garvan Institute of Medical Research
• Collaborator: National Health and Medical Research Council, Australia
• Treatments: Metformin

Criteria

Inclusion Criteria:

• overweight or obese (body mass index >25.0 kg/m2, waist: women>80 cm, men>94cm;

• Mild cognitive impairment (Mild Neurocognitive Disorder), based on DSM-5 criteria;

• Fasting blood glucose <7.0 mmol/L and HbA1c <6.5%;

• Able to undertake neurocognitive testing in English.

• Not participating in another trial of drugs or lifestyle modification to reduce cognitive decline.

Exclusion Criteria:

• Life-threatening illnesses to preclude participation in a 3-year study;

• Contraindications to the use of metformin (severe heart failure or eGFR <40).